Personalised and on-the-spot therapy: deep brain stimulation

Advances

sponsored by Boston Scientific

Author: SponsoredPublished: 4 February 2016

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

Prof Timmermann

A recent study reveals that personalised deep brain stimulation (DBS) can significantly improve the mobility of people with Parkinson’s disease, ultimately helping them to take part in everyday life again


Forty patients at six European centres participated in the VANTAGE study that investigated Boston Scientific’s VerciseTM Deep Brain Stimulation System. Deep brain stimulation is a method to help regulate specific regions of the brain that are associated with abnormal neural activity. The DBS procedure consists of a modest medical device, implanted under the skin of the chest which sends mild electrical impulses to the brain via two insulated cables called leads.

 

The VANTAGE trial highlights the importance of personalised treatment: each person living with Parkinson’s is different and therapy needs to be tailored to each individual. The VerciseTM DBS system’s innovative Multiple Independent Current Control (MICC) technology is designed to help patients cope with their movement disorders. The system’s unique current steering with MICC allows physicians to control the therapeutic current spread. By precise targeting of specific brain areas they can optimise the treatment and minimise unwanted side effects.

“Patients have a very good efficacy of the stimulation, so they reach the best level they can with medication in a very stable therapy, no fluctuations at all”

Professor François Alesch, neurosurgical investigator, Medical University Vienna

Overall, the study shows that the motor skills of patients with a VerciseTM DBS system improved significantly.1 This improvement in motor function came along with an improvement in the daily activities of living.2 Furthermore, people with Parkinson’s could also reduce their medication intake compared to the time prior to the procedure.3

References:

1 Unified Parkinson’s Disease Rating Scale Part III (UPDRS III).

2 Quality of life assessed with Parkinson’s Disease Questionnaire (PDQ-39) Schwab and England and motor diaries.

3 Calculated using levodopa equivalents.


This article is sponsored by Boston ScientificThe information in this article is given for information purposes only and does not represent an endorsement by Parkinson’s Europe of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided

Go Back

Share this story

Comments


Related articles


Global update

Parkinson’s disease symptoms linked to protein deficiency in fruit flies

Scientists in Germany tested the impact of the protein Creld

READ MORE
parkinsonsnet-norway

In my country

Pioneering ParkinsonNet programme launches in Norway

Innovative, patient-centred programme arrives in Norway

READ MORE

Interviews

“Together we can make a difference”

Three Parkinson’s disease campaigners share their advice

READ MORE